Utah Medical Products

UTMD · NASDAQ

$75.07+$0.52 (+0.70%)TodayMarket closed ·
Prev close $74.55

Key indicators

UTMD profitability and balance sheet ratios

EPS $0.8436 in Q2 FY26, down 10.2% on a year earlier.

EPS by quarter
PeriodEPS
Q3 FY24$1.02
Q4 FY24$0.8571
Q1 FY25$0.9187
Q2 FY25$0.939
Q3 FY25$0.8204
Q4 FY25$0.8024
Q1 FY26$0.8176
Q2 FY26$0.8436

Where the money went

Q2 FY26, from revenue to net income

Utah Medical Products brought in $8.5M of revenue in Q2 FY26, −14.3% on a year earlier. 31¢ of every dollar became profit.

Revenue
$8.5M
Costs, expenses and taxes
$5.8M
Net income
$2.7M
Net margin
31.5%

Income statement

Revenue and profit by reporting period

Revenue
Net income
UTMD income statement, quarterly
Line itemQ4 FY25Q1 FY26Q2 FY26
Revenue$9.0M$8.7M$8.5M
Gross profit$5.3M$5.3M$4.8M
Operating income$2.4M$2.6M$2.6M
Net income$2.6M$2.6M$2.7M
Diluted EPS$0.80$0.82$0.84

Balance sheet

What the company owns and owes at period end

Total assets
Total liabilities
UTMD balance sheet, quarterly
Line itemDec 2025Mar 2026Jun 2026
Total assets$122.5M$124.4M$124.6M
Total liabilities$3.3M$4.0M$2.5M
Shareholder equity$119.3M$120.4M$122.0M
Cash and short-term investments$85.8M$87.4M$87.5M
Total debt$0.0M$0.0M$0.0M

Cash flow

Cash in and out from operations, investing and financing

Operating
Investing
Financing
UTMD cash flow, quarterly
Line itemQ4 FY25Q1 FY26Q2 FY26
Operating cash flow$3.5M$3.1M$1.4M
Investing cash flow−$0.1M−$0.1M−$0.1M
Financing cash flow−$2.0M−$1.1M−$1.1M
Capital expenditure−$0.1M−$0.1M−$0.1M
Free cash flow$3.4M$3.0M$1.2M

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.